Drugs / VRC01LS
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02840474 | Apr 2017 → Jan 2020 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02797171 | Mar 2017 → Jun 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02599896 | Nov 2015 → Jul 2018 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02256631 | Jun 2015 → Jun 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03707977 | Jun 2019 → Dec 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC01LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02256631 ↗ |
| Known as | VRC-HIVMAB080-00-AB | “VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB060-00-AB (VRC01) are human MAb targeted to the CD4 binding site of HIV-1.” NCT02599896 ↗ |
| Action | Inhibit | “VRC01LS administration resulted in a smaller average decline (0.8 ± 0.8 log10 copies/mL), and 3 out of 7 participants showedno change in VL.” PMID 39989458 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “VRC01, VRC01LS, and VRC07-523LS are anti-HIV neutralizing monoclonal antibodies” NCT02256631 ↗ |
| Route | Intravenous | “Participants will get VRC01LS through either: * A needle in an arm vein or * A small needle placed into the fatty tissue under the skin of the abdomen, thigh, or arm.” NCT02599896 ↗ |
| Route | Subcutaneous | “Participants will get VRC01LS through either: * A needle in an arm vein or * A small needle placed into the fatty tissue under the skin of the abdomen, thigh, or arm.” NCT02599896 ↗ |
| Target | CD4 | “T-cell surface antigen CD4 binding agent” CHEMBL4298127 ↗ |